Showing results (101-110 of 200) with videos related to
Sort By:
Pageof 20
Investigational New Drugs|February 1, 1990
An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinomaM L McMaster, F A Greco, D H Johnson, et al.Seminars in Oncology|August 1, 1997
A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancerR Birch, C H Weaver, J D Hainsworth, et al.Cancer|February 15, 1997
Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trialJ D Hainsworth, J Jolivet, R Birch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trialD H Johnson, F A Greco, J Strupp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancerJ D Hainsworth, H A Burris, J B Erland, et al.Annals of Internal Medicine|July 1, 1982
Advanced extragonadal germ-cell tumors. Successful treatment with combination chemotherapyJ D Hainsworth, L H Einhorn, S D Williams, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1985
Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trialJ D Hainsworth, S D Williams, L H Einhorn, et al.Oncology|January 1, 1992
Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trialD H Johnson, J D Hainsworth, R DeVore, et al.Cancer|June 1, 1994
Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II studyD S Thompson, J D Hainsworth, K R Hande, et al.American Journal of Clinical Oncology|August 1, 1991
Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapyJ D Hainsworth, G A Omura, A Khojasteh, et al.Pageof 20